Based on these observations, clinical trials in adult patients have evaluated the toxicity, pharmacokinetics, and therapeutic effect of IFNγ on HIV-1 p24 load, AIDS-associated complex (ARC), and AIDS-associated Kaposi’s sarcoma (KS) (49–52). Here, IFNG is linked to AIDS.